(Bloomberg) — Blood tests that can tell whether patients have been infected with the new coronavirus will get tighter oversight from U. S. health regulators, after some manufacturers made allegedly false or inappropriate claims and questions arose about the accuracy of some tests.
The Food and Drug Administration said Monday that makers of the tests, which since mid-March have been allowed to be sold without any government sign-off, will have to apply for authorization within 10 days of their products coming to market.
The FDA also laid out requirements tests must meet to gain clearance.
While the FDA’s original March 16 policy was meant to provide flexibility, “flexibility never meant we would allow fraud,” the health agency said in a statement announcing the policy change. “We unfortunately see unscrupulous actors marketing fraudulent test kits and using the pandemic as an opportunity to take advantage of Americans’ anxiety.”
The FDA has given emergency authorizations to 12 antibody tests and said that 200 are currently in the review process.
For more articles like this, please visit us at bloomberg.com
©2020 Bloomberg L.
P.
